Lake Forest, CA - Rubicon Biotechnology, LLC is pleased to announce that it was awarded a SBIR Phase I grant by the National Eye Institute titled “Targeted Hsp72 as a Therapeutic for Central Retinal Artery Occlusion”. Rubicon is collaborating with Drs. Michael Gorin and Anna Matynia and their teams at the Stein Eye Institute at…
Read more
About: admin
Recent Posts by admin
Rubicon Announces Publication in JACC
Lake Forest, CA - Rubicon Biotechnology, LLC announces the publication of preclinical results for our lead platform technology, Fv-Hsp72, for the treatment of stress injuries caused by a myocardial infarction. The article titled “Cardioprotective effects of HSP72 administration on ischemia-reperfusion injury", by collaborators from Rubicon and the laboratory of Jagat Narula, MD, PhD, Associate Dean for…
Read more
Rubicon Signs Agreement with Foothill Scientific
Lake Forest, CA - Rubicon Biotechnology and Foothill Scientific Associates (FSA) announce an agreement in which Rubicon will contract with Foothill Scientific Associates for services related to government grants, contracting, product development and business development. Foothill Scientific Associates (FSA) is a network of professionals in the areas of Drug Development, Program Management, Engineering, Human Resource…
Read more
Rubicon Announces Heat Shock Protein Publication
Lake Forest, CA - Rubicon Biotechnology, LLC announces the publication of a review article called "Targeted Heat Shock Protein 72 for Cytoprotection" by Dr. Missag Parseghian, Chief Scientific Officer of Rubicon, in the Annals of the New York Academy of Sciences.Dr. Stephen Hobson of Seacoast Scientific, Inc. and Richard Richieri, COO of Rubicon also contributed to…
Read more
Recent Comments by admin
No comments by admin yet.